We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04560569
Previous Study | Return to List | Next Study

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04560569
Recruitment Status : Recruiting
First Posted : September 23, 2020
Last Update Posted : September 29, 2021
Sponsor:
Information provided by (Responsible Party):
Frontier Biotechnologies Inc.

Tracking Information
First Submitted Date  ICMJE September 17, 2020
First Posted Date  ICMJE September 23, 2020
Last Update Posted Date September 29, 2021
Estimated Study Start Date  ICMJE November 30, 2021
Estimated Primary Completion Date November 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 17, 2020)
Proportion of participants with ≥0.5 log10 reduction in HIV-1 RNA viral load from baseline (Day 7) to Day 14 as compared to the control period from Day 0 to Day 7. [ Time Frame: Day 14 ]
Proportion of participants (%) achieving a viral load reduction of at least 0.5 log from baseline (Day 7)
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 17, 2020)
  • Mean change in HIV-1 RNA levels (log10 copies/mL) from baseline (Day 7) to Day 14 as compared to the control period from Day 0 to Day 7. [ Time Frame: Day 14 ]
    Mean change in HIV-1 RNA levels from Day 7 to Day 14
  • Mean change in CD4+/CD8+ T cell count from baseline (Day 7) to Day 14 as compared to the control period from Day 0 to Day 7. [ Time Frame: Day 14 ]
    Mean change in CD4+/CD8+ T cell count from Day 7 to Day 14
  • Percentage of participants achieving HIV-1 RNA <200 copies/mL at the EOT. [ Time Frame: Week 25/EOT ]
    Percentage of participants achieving HIV-1 RNA <200 copies/mL
  • Mean change in HIV-1 RNA levels (log10 copies/mL) during the course of Treatment Phase [ Time Frame: Through Week 25/EOT ]
    Mean change in HIV-1 RNA levels from Day 0 to EOT
  • Mean change in HIV-1 RNA levels (log10 copies/mL) from baseline (Day 7) to EOT. [ Time Frame: Week 25/EOT ]
    Mean change in HIV-1 RNA levels from Day 7 to EOT
  • Mean change in CD4+/CD8+ T cell count from baseline (Day 7) to EOT. [ Time Frame: Week 25/EOT ]
    Mean change in CD4+/CD8+ T cell count from Day 7 to EOT
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
Official Title  ICMJE A Multicenter, Two-Arm, 24-Week Study of Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
Brief Summary The primary objectives are to assess the antiviral activity, clinical safety and tolerability parameters of albuvirtide/3BNC117 combination therapy in reducing HIV-1 viral load during the 1-week induction period treatment period.
Detailed Description This is a Phase 2, multi-center study to evaluate the efficacy, safety, and tolerability of ABT/3BNC117 combination in conjunction with an existing failing antiretroviral therapy (ART) for 1 week, and then with optimized background regimen (OBR) for 24 weeks, respectively. A total of 20 eligible subjects who demonstrate evidence of HIV-1 replication despite ongoing antiretroviral therapy with documented genotypic and/or phenotypic resistance to multiple classes of HIV drugs (3 classes or more) will be enrolled. Patients must have been treated with HAART for at least 6 months and be failing or have recently failed (i.e., in the last 8 weeks) therapy to determine baseline viral load.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE HIV/AIDS
Intervention  ICMJE
  • Drug: Albuvirtide
    Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
    Other Name: ABT
  • Drug: 3BNC117 Antibody
    Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120
    Other Name: 3BNC117
Study Arms  ICMJE
  • Experimental: Group A
    ABT weekly and 3BNC117 bi-weekly
    Interventions:
    • Drug: Albuvirtide
    • Drug: 3BNC117 Antibody
  • Experimental: Group B
    both ABT and 3BNC117 treatment bi-weekly
    Interventions:
    • Drug: Albuvirtide
    • Drug: 3BNC117 Antibody
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 17, 2020)
20
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 1, 2022
Estimated Primary Completion Date November 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Males and females, age ≥ 18 years;
  2. HIV-1 seropositive with documented HIV-1 infection by official, signed, written history (e.g. Laboratory report)
  3. Receiving a combination antiretroviral therapy (cART) (failing regimen) for at least 8 weeks before Screening and are willing to continue on the failing regimen during the Screening Phase and up to Day 14 of the Treatment Phase, OR have failed in the past 8 weeks of Screening, are off therapy and are willing to stay off therapy until Day 14 of the Treatment Phase;
  4. Plasma HIV-1 RNA ≥ 1000 copies/mL at the Screening Visit and documented detectable viral load (HIV-1 RNA >200 copies/ml) within the last 3 months prior to the Screening Visit;
  5. Highly treatment-experienced HIV-infected patients with genotypic and/or phenotypic resistance to at least one ARV drug for each of three or more drug classes of antiretroviral medications at the Screening Visit and have difficulty in constructing a viable suppressive regimen;
  6. Have full viral sensitivity/susceptibility to at least one approved antiretroviral agent, other than ABT and 3BNC117, as determined by genotypic and/or phenotypic ARV drug resistance tests at screening, and such agent can be used as a component of OBR;
  7. Be willing to remain on treatment without any changes or additions to the OBR regimen, except for toxicity management or upon meeting criteria for treatment failure;
  8. Have a life expectancy that is > 9 months;
  9. Laboratory values at Screening of:

    1. Absolute neutrophil count (ANC) ≥ 750/mm3;
    2. Hemoglobin (Hb) ≥ 10.5 gm/dL (male) or ≥ 9.5 gm/dL (female);
    3. Platelets ≥ 75,000 /mm3;
    4. Serum alanine transaminase (SGPT/ALT) < 1.25 x upper limit of normal (ULN);
    5. Serum aspartate transaminase (SGOT/AST) < 1.25 x ULN;
    6. Serum total bilirubin within normal range; and
    7. Creatinine ≤ 1.5 x ULN.
  10. Clinically normal resting 12-lead electrocardiogram (ECG) at the Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator
  11. Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at the Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug; and
  12. Willing and able to participate in all aspects of the study, including use of IV medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.

Note: Subjects diagnosed with either substance dependence or substance abuse or any history of a concomitant condition (e.g., medical, psychological, or psychiatric) may be enrolled if, in the opinion of site investigator these circumstances would not interfere with the subject's successful completion of the study requirements.

Exclusion Criteria:

  1. Subject having ≥0.5 log10 reduction in HIV-1 RNA viral load from the Screening Visit to Baseline Visit (Day 0).

    Note: This criterion will be evaluated prior to randomization at T1 Visit (Day 7).

  2. Any active infection or malignancy requiring acute therapy;
  3. Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg);
  4. Hepatitis C infection as manifest by positive anti-HCV antibody and positive HCV RNA assay at the time of screening;
  5. Grade 4 DAIDS laboratory abnormality;
  6. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study;
  7. Unexplained fever or clinically significant illness within 1 week prior to the first study dose;
  8. Any vaccination within 2 weeks prior to the first study dose;
  9. Prior exposure to albuvirtide or 3BNC117
  10. Subjects weighing <35kg;
  11. History of anaphylaxis to any oral or parenteral drugs;
  12. Use of any fusion inhibitors (T20) and broadly neutralizing monoclonal antibody prior to the Screening Visit, including the investigational drugs, or having documented genotypic and/or phenotypic resistance to fusion inhibitors;
  13. Participation in an experimental drug trial(s) within 30 days of the Screening Visit;
  14. Any known allergy or antibodies to the study drug or excipients;
  15. Treatment with any of the following:

    1. Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit;
    2. Immunosuppressants or immunomodulating agents within 60 days prior to the screening visit; or
    3. Oral or parenteral corticosteroids within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy 5 mg/day will be excluded with the following exception:

      • Subjects on inhaled, nasal, or topical steroids will not be excluded.
  16. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Xiaomei Wang, MBBS, MS 610-888-3658 wangxiaomei@frontierbiotech.com
Contact: Cheng Yao, M.D. (+86)025-69648387 yaocheng@frontierbiotech.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04560569
Other Study ID Numbers  ICMJE ABT-3BNC117_203
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Frontier Biotechnologies Inc.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Frontier Biotechnologies Inc.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Cheng Yao, M.D. Frontier Biotechnologies Inc.
PRS Account Frontier Biotechnologies Inc.
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP